Sigma-Aldrich Corporation
(
SIAL
) announced the signing of an agreement with AB Sciex to distribute
its portfolio ofmass spectrometry-based tagging chemistries. The
consumables, sold as SCIEX iChemistry Solutions, are used
inproteomics applications in basic research and applied markets. AB
SCIEX is a global leader in mass spectometry products and helps
scientists and laboratory analysts to address complex challenges in
this field.
Sigma Aldrich expects the agreement to be a shot in the arm for
the research work on mass spectrometry-based protein as the
scientists will get access to high-quality solutions for workflows
to enable the study of the proteome. This will be particularly
helpful in the Asia-Pacific region.
Sigma-Aldrich will be able to provide a complete suite of
solution to mass spectrometry users as well as biologists and
chemists to adopt mass spectrometry to improve their analyses. The
company has already added 60,000 antibodies that will enable the
researchers to accurately discern dynamic states of proteins in key
pathways throughout the proteome.
Sigma-Aldrich, a life science and specialty chemical company,
released its second-quarter 2012 earnings in July 2012. The company
posted adjusted earnings of 97 cents per share in the quarter, in
line with the Zacks Consensus Estimate but ahead of the year-ago
earnings of 93 cents per share. Profit, as reported, marginally
increased to $115 million or 94 cents per share in the quarter from
$113 million or 91 cents a year ago.
Revenues came in at $664 million in the quarter, up 4% year over
year but below the Zacks Consensus Estimate of $673 million.
Acquisitions contributed 6% to the growth while foreign exchange
translation had an unfavorable impact of 5%. The company saw growth
across its Research Chemicals and Fine Chemicals ("SAFC")
divisions.
Moving ahead, Sigma-Aldrich expects organic growth to be in
low-to-mid single digits in 2012, down from the earlier expectation
of mid single-digits. Macroeconomic uncertainties may hinder its
Research Chemicals business whereas growth in Bioscience and Hitech
is expected to drive SAFC sales for the remainder of the year. The
acquisitions of BioReliance and Research Organics are expected to
boost sales by 6%.
Sigma-Aldrich, a close peer of
Bayer AG
(
BAYRY
), currently maintains a Zacks #4 Rank, which translates into a
short-term (1 to 3 months) Sell rating. We have a long-term Neutral
recommendation on the stock.
BAYER A G -ADR (BAYRY): Free Stock Analysis
Report
SIGMA ALDRICH (SIAL): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research